By Fineline Cube Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that Risvutatug Rezetecan (HS-20093), its proprietary B7-H3-targeted antibody-drug conjugate (ADC), has met the primary endpoint of overall survival (OS) in the pivotal Phase III ARTEMIS-008 trial for patients with small cell lung cancer (SCLC) whose disease progressed or relapsed following platinum-based therapy.
Clinical Trial Results
| Endpoint | Result (HS-20093 vs. Topotecan) |
|---|---|
| Primary Endpoint | Statistically significant and clinically meaningful improvement in Overall Survival (OS) |
| Secondary Endpoints | Consistent benefits observed across all secondary endpoints including Progression-Free Survival (PFS) |
| Safety Profile | Consistent with previous studies; no new safety signals identified |
| Analysis Type | Pre-specified interim analysis |
| Patient Population | SCLC patients with disease progression/relapse after platinum-based therapy |
The positive results from the ARTEMIS-008 trial represent a potential breakthrough for SCLC treatment, a disease area with limited therapeutic options and poor long-term outcomes.
Drug Profile & Mechanism of Action
- Molecule: Risvutatug Rezetecan (HS-20093)
- Class: B7-H3-targeted antibody-drug conjugate (ADC)
- Structure: Fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor (TOPOi) payload
- Target: B7-H3 (CD276), an immune checkpoint protein overexpressed in multiple solid tumors
- Developer: Independently developed by Hansoh Pharmaceutical
B7-H3 represents an emerging target in oncology with expression across various tumor types while showing limited expression in normal tissues, potentially offering a favorable therapeutic window.
Development Pipeline Status
China (Hansoh Pharma)
- Phase III: Osteosarcoma, Small Cell Lung Cancer, Non-Small Cell Lung Cancer
- Proof-of-Concept Studies: Head and neck cancer, prostate cancer, esophageal squamous cell carcinoma, colorectal cancer, and other solid tumors
Global (GlaxoSmithKline)
- Licensing Agreement: Exclusive global license granted in December 2023 (excluding Chinese Mainland, Hong Kong, Macau, and Taiwan)
- Current Status: GSK advancing Phase I and Phase III clinical trials overseas
Strategic Partnership with GSK
| Deal Component | Detail |
|---|---|
| Partner | GlaxoSmithKline (GSK) |
| Agreement Date | December 2023 |
| Territory | Global (excluding Greater China region) |
| Rights Granted | Exclusive license for development, manufacturing, and commercialization |
| Strategic Rationale | Leverages GSK’s global oncology expertise and commercial infrastructure |
The partnership validates the potential of HS-20093 as a best-in-class B7-H3 ADC and provides Hansoh with significant non-dilutive funding and global development capabilities.
Market Impact & Commercial Potential
- SCLC Market Opportunity: Addresses significant unmet need in second-line SCLC with limited effective treatments
- Competitive Landscape: Potential to become standard of care in relapsed/refractory SCLC if approved
- Revenue Potential: Substantial milestone payments and royalties from GSK partnership plus direct sales in China
- Platform Validation: Success validates Hansoh’s ADC platform and B7-H3 targeting approach across multiple indications
Small cell lung cancer accounts for approximately 10-15% of all lung cancer cases globally, with most patients experiencing disease progression within months of initial treatment. The demonstrated survival benefit represents a meaningful advance for this patient population.
Regulatory Pathway & Next Steps
- China NMPA: Submission of New Drug Application (NDA) based on ARTEMIS-008 results
- Global Regulatory Strategy: GSK to lead regulatory submissions in international markets
- Additional Indications: Continued development in osteosarcoma, NSCLC, and other solid tumors
- Commercial Preparation: Manufacturing scale-up and market access planning
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory approvals, and commercial expectations. Actual results may differ due to risks including final trial data, regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech